Theranostics Nuclear Medicine in Prostate Cancer
Open Access
- 5 November 2024
- journal article
- review article
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (11) , 1483
Abstract
Theranostic Nuclear Medicine is based on the idea of combining the same molecule (or drug) with different radioisotopes for both diagnosis and treatment, a concept that emerged in the early 1940s with the use of radioactive iodine for thyroid diseases. Theranostic Nuclear Medicine has since expanded to diseases of higher incidence, such as prostate cancer, with several imaging methods used to assess the extent of the disease and the corresponding radiopharmaceuticals used for treatment. For example, by detecting osteoblastic metastases by bone scintigraphy, corresponding radiopharmaceuticals with therapeutic properties can be administered to eliminate or reduce pain associated with metastases and/or determine overall survival gain. The purpose of this review is to discuss the role of Theranostic Nuclear Medicine in prostate cancer, addressing the main diagnostic imaging studies with their corresponding treatments in the Theranostic model.Keywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2021/10265-8)
This publication has 112 references indexed in Scilit:
- 225Ac‐PSMA‐617‐targeted alpha therapy for the treatment of metastatic castration‐resistant prostate cancer: A systematic review and meta‐analysisThe Prostate, 2021
- Synthesis, Labeling and Preclinical Evaluation of a Squaric Acid Containing PSMA Inhibitor Labeled with 68Ga: A Comparison with PSMA‐11 and PSMA‐617ChemMedChem, 2020
- Modular Synthesis of DOTA‐Metal‐Based PSMA‐Targeted Imaging Agents for MRI and PET of Prostate CancerChemistry – A European Journal, 2019
- Recurrent prostate cancer detection with anti-3-[18F]FACBC PET/CT: comparison with CTEuropean Journal of Nuclear Medicine and Molecular Imaging, 2016
- Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- PSMA as a target for radiolabelled small moleculesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesionsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2012
- 18F-Fluoride PET/CT is highly effective for excluding bone metastases even in patients with equivocal bone scintigraphyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2012
- [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECHEuropean Journal of Nuclear Medicine and Molecular Imaging, 2012
- RADIOACTIVE IODINE THERAPYJAMA, 1946